BNGO_OUT_1 [2025-04-02 13:01:26 -0400] 3169 Bytes | 878 tokens | Cum: 878 tkns (10.97% of 8k)
==========================================================================

Alright, let’s light it up, because it's 1:01:25 PM on Wed Apr 02, 2025 -0400, and I'm charging into Bionano Genomics (BNGO), popping from 3.1 to 3.5484. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

--- COMPANY PROFILE ---
Company: Bionano Genomics (BNGO)
IPO: 2018-08-01 (6 Years Ago)
Market Cap: $8,471,804
Shares Outstanding: 2,730,000
Industry: LABORATORY ANALYTICAL INSTRUMENTS
Exchange: XNAS
Description: Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.

Here's the first list of news for Bionano Genomics:

C1 - Apr-01-25 12:26PM - Q4 2024 Bionano Genomics Inc Earnings Call
C2 - Apr-01-25 12:26PM 03:04AM - Bionano Genomics Inc (BNGO) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and ...
C3 - Mar-31-25 08:30PM - Bionano Genomics (BNGO) Q4 2024 Earnings Call Transcript
C4 - Mar-31-25 08:30PM 08:11PM - Bionano Genomics, Inc. (BNGO) Q4 2024 Earnings Call Transcript
C5 - Mar-31-25 08:30PM 04:01PM - Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025
C6 - Mar-24-25 08:00AM - Study Using OGM in Neural Tube Defects Reveals Previously Unreported Variants and Candidate Genes with Potential Links to the Devastating Birth Defect
C7 - Mar-18-25 08:00AM - Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) 2025 Annual Meeting
C8 - Mar-14-25 08:00AM - Bionano to Report Fourth Quarter and Full Year 2024 Financial Results and Host a Conference Call Webcast on March 31, 2025

Prior AI Reports for BNGO:
1. 2025-04-01 – Score: 35 – Target: 3.4100 – Highs: – / – / –
financial-analysis-reveals-distress-signals-for-company

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Bionano Genomics (BNGO)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

BNGO_OUT_3 [2025-04-02 13:01:28 -0400] 321 Bytes | 94 tokens | Cum: 974 tkns (12.17% of 8k)
==========================================================================

Showing C1 (chunk 1 of 1):

[INFO] Your document request exceeded 20000 characters. If you need more, please request additional documents separately.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BNGO_OUT_5 [2025-04-02 13:01:29 -0400] 939 Bytes | 279 tokens | Cum: 1276 tkns (15.95% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T00:30:14Z - Bionano Genomics (BNGO) Q4 2024 Earnings Call Transcript...
A2 - 2025-03-31T21:05:46Z - 12 Health Care Stocks Moving In Monday's After-Market Session - AquaBounty Techs (NASDAQ:AQB), Adver...
A3 - 2025-03-31T20:15:14Z - Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025...
A4 - 2025-03-31T20:01:00Z - Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025 - Bi...
A5 - 2025-03-31T14:00:19Z - Here are the major earnings after the close today...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

BNGO_OUT_7 [2025-04-02 13:01:32 -0400] 321 Bytes | 94 tokens | Cum: 1372 tkns (17.15% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1):

[INFO] Your document request exceeded 20000 characters. If you need more, please request additional documents separately.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BNGO_OUT_9 [2025-04-02 13:01:33 -0400] 925 Bytes | 297 tokens | Cum: 1727 tkns (21.59% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-03T19:34:00Z - Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
B2 - 2024-12-31T20:26:00Z - Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway
B3 - 2024-10-10T12:00:00Z - Bionano Announces Preliminary 3Q 2024 Revenues and Cash
B4 - 2024-07-17T17:35:17Z - 10 Consumer Discretionary Stocks With Whale Alerts In Today's Session - Benzinga
B5 - 2024-05-08T22:30:14Z - Bionano Genomics (BNGO) Q1 2024 Earnings Call Transcript
B6 - 2024-05-08T20:01:00Z - Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BNGO_OUT_11 [2025-04-02 13:01:37 -0400] 733 Bytes | 202 tokens | Cum: 1931 tkns (24.14% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/03/3004131/0/en/Bionano-Announces-10-Million-Registered-Direct-Offering-Priced-At-the-Market-under-Nasdaq-Rules.htmlBionano Genomics announced a $10 million registered direct offering, with the proceeds to be used for general corporate purposes. The offering includes the sale of common stock and warrants to institutional investors.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BNGO_OUT_13 [2025-04-02 13:01:38 -0400] 1064 Bytes | 267 tokens | Cum: 2288 tkns (28.60% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 8-K Item 2.02 Results of Oper and Fin Cond.

On March 31, 2025, Bionano Genomics, Inc. (the Company) issued a press release announcing certain performance results for the fourth quarter of 2024 and for the year ended December 31, 2024. A copy of the press release is...

S2 - 2025-03-31 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

You should read the following discussion and analysis of our financial condition and results of operations together in conjunction with our financial statements and the related notes i...

S3 - 2025-03-31 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

You should read the following discussion and analysis of our financial condition and results of operations together in conjunction with our financial statements and the related notes i...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BNGO_OUT_15 [2025-04-02 13:01:43 -0400] 1098 Bytes | 279 tokens | Cum: 2569 tkns (32.11% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 2.02 Results of Operations and Financial Condition.

On March 31, 2025, Bionano Genomics, Inc. (the Company) issued a press release announcing certain performance results for the fourth quarter of 2024 and for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1and incorporated herein by reference.

The information contained or incorporated in this Item 2.02 to Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Forwar

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BNGO_OUT_17 [2025-04-02 13:01:56 -0400] 5400 Bytes | 1582 tokens | Cum: 4265 tkns (53.31% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+------------------------+
| Volume: 86,008 | Perf Month: -11.11% | Option/Short: No / Yes | Sales Y/Y TTM: -14.79% |
+---------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 205.37K | Perf Quarter: -79.55% | Short Float: 18.68% | ROE: -170.33% |
+---------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 0.79 | Index: - | Short Ratio: 2.47 | ROI: -286.79% |
+---------------------+-----------------------+------------------------+------------------------+
| RSI (14): 42.21 | Market Cap: 10.56M | Short Interest: 0.51M | Sales Surprise: 36.05% |
+---------------------+-----------------------+------------------------+------------------------+
| ATR (14): 0.37 | Shs Outstand: 2.73M | Beta: 2.43 | EPS Surprise: -107.19% |
+---------------------+-----------------------+------------------------+------------------------+
| SMA20: 3.85% | Shs Float: 2.72M | Sales Q/Q: -23.86% | P/E: - |
+---------------------+-----------------------+------------------------+------------------------+
| SMA50: -24.45% | Inst Own: 10.23% | Sales past 5Y: 33.03% | Earnings: Mar 31 AMC |
+---------------------+-----------------------+------------------------+------------------------+
| SMA200: -82.12% | Insider Own: 0.36% | Employees: 100 | |
+---------------------+-----------------------+------------------------+------------------------+
| Perf Week: 12.53% | Insider Trans: 0.00% | Debt/Eq: 0.77 | |
+---------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Bionano Genomics, Inc. (BNGO) by Dixon Jonathan V. (General Counsel) on 2025-03-14
- Stock Option (Right to Buy): 6559 shares at $0 (D)

Inside Trans: Bionano Genomics, Inc. (BNGO) by Adamchak Mark (Principal Accounting Officer) on 2025-03-14
- Stock Option (Right to Buy): 3029 shares at $0 (D)

Inside Trans: Bionano Genomics, Inc. (BNGO) by Holmlin R. Erik (President and CEO) on 2025-03-14
- Common Stock: 198 shares at $3.47 (D) Footnote: The reporting person is reporting the withholding by the Issuer of an aggregate of 198 shares of common stock in connection with shares that vested on March 14, 2025 pursuant to an PSU award granted on May 12, 2021, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the PSU award.
- Stock Option (Right to Buy): 17449 shares at $0 (D)

Inside Trans: Bionano Genomics, Inc. (BNGO) by OLDAKOWSKI MARK (Chief Operating Officer) on 2025-03-14
- Stock Option (Right to Buy): 6966 shares at $0 (D)

Inside Trans: Bionano Genomics, Inc. (BNGO) by Chaubey Alka (Chief Medical Officer) on 2025-03-14
- Stock Option (Right to Buy): 6966 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 36579000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -204103000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 3.5276
Average Volume: 89545.74
30-Day High: 4.1
30-Day Low: 2.79

[Detailed Financials: Q2 2024]
- Total Assets: $129,364,000.0
- Total Liabilities: $49,027,000.0
- Total Equity: $80,337,000.0
- Current Assets: $60,568,000.0
- Current Liabilities: $37,175,000.0

[Income Statement: Q2 2024]
- Revenue: $7,771,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.24

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $5,674,000.0

[Detailed Financials: Q1 2024]
- Total Assets: $157,995,000.0
- Total Liabilities: $75,224,000.0
- Total Equity: $82,771,000.0
- Current Assets: $85,611,000.0
- Current Liabilities: $58,506,000.0

[Income Statement: Q1 2024]
- Revenue: $8,769,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.6

[Cash Flow Statement: Q1 2024]
- Net Cash Flow: $-2,189,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

BNGO_OUT_19 [2025-04-02 13:01:59 -0400] 676 Bytes | 167 tokens | Cum: 4708 tkns (58.85% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

BNGO_IN_21 [2025-04-02 13:02:00 -0400] 126 Bytes | 29 tokens | Cum: 4789 tkns (59.86% of 8k)
==========================================================================

====================================
[2025-04-02 13:02:00] # Analysis Completed
Elapsed Time: 34.41 seconds